Upstream Bio, Inc. (UPB)
Nasdaq · Healthcare · Biotechnology
$4.85−3.77%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $266M
- 52-week range
- $4.67 – $33.68
- 52-week change
- −73.43%
- EPS (trailing)
- −$2.88
- Next earnings
- Nov 4, 2026
Fiscal year to Dec 2025
- Revenue
- $2.9M (+20.42%)
- Net income
- −$143M
- Operating margin
- −5618.8%
- Diluted EPS
- −$2.66
- Free cash flow
- −$133M
From the company’s annual report on SEC EDGAR.
About Upstream Bio, Inc.
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
Headquarters: Waltham, United States · 75 employees · upstreambio.com